Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

LCTX Debt Repayment

Cash used to repay borrowings during the period.

Lineage Cell Therapeutics, Inc.AMEX: LCTX

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment grows, but more slowly than its trailing trend

Q1 FY2026 debt repayment of $14K (cash outflow) rose 0.0% year over year, behind the +7.3% change in trailing-twelve-month debt repayment. Sequentially, it fell 6.7% from the prior quarter. Over 3 fiscal years it compounded at +22.6% a year.

Context

  • Debt repayment amounted to 0.4% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Debt repayment grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +7.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14K-6.7% QoQ
Last fiscal yearDec 2025
-$59K+9.3% YoY
LTMMar 2026
-$59K+7.3% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year+9.3%——
3-year CAGR+22.6%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(59K) USD
Year-over-year change
-9.3%

Debt Repayment vs competitors

How LCTX compares with its peers on the latest reported figures

  • LCTX's LTM Mar 2026 debt repayment of $59K is the 3rd largest of the 4 companies compared; the peer median is $2.73M.
  • Its year-over-year change of +7.3% is the highest of 3, against a peer median of -147.0%.
  • Debt repayment amounts to 0.4% of revenue for LCTX, versus a peer median of 17.1%.
LCTX Competitors Peer median
Debt Repayment for LCTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$8.48M -219.4%—31.9%
MESOMesoblast LimitedLTM Jun 2026$2.73M -74.6%+30.7%2.3%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$59K +7.3%+22.6%0.4%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding LCTX) $2.73M-147.0%+30.7%17.1%

Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.27M)(26.35M)(21.49M)(18.61M)(63.53M)
Depreciation & Amortization873K727K692K609K699K
Deferred Income Tax(6M)0(1.8M)0(5.28M)
Stock-Based Compensation3.52M4.29M4.64M5.08M4.75M
Change in Working Capital21.11M18.67M(10.8M)(8.77M)(4.11M)
Accounts Receivables(857K)50.31M(446K)106K(316K)
Inventory(72K)0000
Accounts Payables21.65M(18.7M)(2.3M)(1.68M)2.27M
Other Working Capital308K(12.94M)(8.06M)(7.19M)(6.07M)
Other Non-Cash Items202K3.73M195K(1.4M)48.55M
Operating Cash Flow(23.56M)1.06M(28.57M)(23.09M)(18.92M)
Capital Expenditures(354K)(413K)(674K)(565K)(522K)
Acquisitions (Net)10.09M45.75M000
Purchases of Investments6.02M(53.41M)(16.4M)(8.76M)(14.94M)
Sales of Investments(6.02M)7.67M63.53M7.02M2M
Other Investing Activities14K(45.75M)000
Investing Cash Flow9.75M(46.16M)46.45M(2.31M)(13.46M)
Debt Repayment(20K)(32K)(54K)(54K)(59K)
Common Stock Issued30.87M148K6.63M35.88M27.03M
Common Stock Repurchased(54K)(17K)(37K)(23K)0
Dividends Paid00000
Other Financing Activities6.14M1.53M(37K)58K(16K)
Financing Cash Flow36.93M1.63M6.42M35.86M26.95M
Effect of Forex Changes(20K)(873K)(250K)(95K)396K
Net Change in Cash23.09M(44.34M)24.06M10.36M(5.03M)
Free Cash Flow(23.92M)646K(29.24M)(23.66M)(19.44M)

Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.